Jhanelle Gray
Moffitt Cancer Center · H. Lee Moffitt Cancer Center and Research Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jhanelle Gray as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:41 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06745882 · Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLCH. Lee Moffitt Cancer Center and Research Institute · recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph1NCT03177291 · Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLCH. Lee Moffitt Cancer Center and Research Institute · completed · Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer · principal investigator
- Ph1/Ph2NCT03164772 · Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLCLudwig Institute for Cancer Research · completed · Metastatic Non-small Cell Lung Cancer, NSCLC · study chair
- Ph1/Ph2NCT02638090 · Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)H. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Lung Cancer, Non-small Cell Lung Cancer · principal investigator
- Ph2NCT02513563 · AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung CancerH. Lee Moffitt Cancer Center and Research Institute · completed · Lung Cancer · principal investigator
- Ph1/Ph2NCT02466568 · Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the LungH. Lee Moffitt Cancer Center and Research Institute · withdrawn · Lung Cancer, Adenocarcinoma of the Lung · principal investigator
- Ph1/Ph2NCT02118337 · A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced MalignanciesMedImmune LLC · completed · Select Advanced Malignancies, Kidney Cancer, Clear Cell Renal Cell Carcinoma · principal investigator
- Ph1NCT01859026 · A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR MutationH. Lee Moffitt Cancer Center and Research Institute · completed · Lung Cancer, Non-Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT01433172 · Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung CancerH. Lee Moffitt Cancer Center and Research Institute · completed · Lung Cancer, Adenocarcinoma · principal investigator
- Ph1NCT00738751 · Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract CancersH. Lee Moffitt Cancer Center and Research Institute · completed · Lung Cancer, Head and Neck Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Molecular MedicineP30CA076292 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · fiscal years 2020 to 2026 · $47,589 awarded in 2026Same name and institution; not confirmed by an ID
- Exisulind for Chemoprevention of Lung CancerU01CA101222 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · fiscal years 2007 · $1,000,956 awarded in 2007Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:41 UTC. The ranking covers the 200 most relevant of 274 PubMed records, and a shared surname and initials can bring in a namesake. All 274 on PubMed
- Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.N Engl J Med · 20185,606 citationsRCR 203.9
- Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.N Engl J Med · 20184,615 citationsRCR 168.8
- Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.N Engl J Med · 20173,900 citationsRCR 133.1
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.N Engl J Med · 20202,543 citationsRCR 114.6
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.N Engl J Med · 20182,335 citationsRCR 81.4
- Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.N Engl J Med · 20111,508 citationsRCR 38.6
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.J Clin Oncol · 20221,268 citationsRCR 88.1
- Long-term safety and efficacy of factor IX gene therapy in hemophilia B.N Engl J Med · 20141,043 citationsRCR 31.1
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.J Clin Oncol · 2020919 citationsRCR 38.3
- Anterior cingulate cortex and response conflict: effects of frequency, inhibition and errors.Cereb Cortex · 2001801 citationsRCR 22.3